Market Research Logo

Global Preventive Asthma Drugs Market 2015-2019

Global Preventive Asthma Drugs Market 2015-2019

About asthma

According to the Global Initiative for Asthma, asthma is a chronic disease, which is characterized by wheezing, shortness of breath, chest tightness, and cough over a period of time. The symptoms worsen due to the increased secretion of mucus, bronchoconstriction, and thickening of the walls of the airways, resulting in difficulty in expiration. According to the American Academy of Allergy, Asthma, and Immunology, asthma is classified into four types: exercise-induced, allergic, occupational, and childhood. Also, asthma can be classified into two categories: allergic and non-allergic, as per the classification of Asthma and Allergy Foundation of America. Asthma can be managed by preventive medications, which should be administered to the patient regularly to improve his quality of life by controlling the exacerbations.

Technavio's analysts forecast the global preventive asthma drugs market to grow at a CAGR of 5.20% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global preventive asthma drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sale of the following classes of drugs used to treat asthma:

  • Immunosuppressants
  • Leukotriene antagonists
  • Mast cell stabilizers
  • Corticosteroids
  • Combination of LABA/ ICS
This report includes a discussion of the market in the following three regions:
  • Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
  • EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
  • APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India
Technavio's report, Global Preventive Asthma Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the global preventive asthma drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions
  • Americas
  • APAC
  • EMEA
Key vendors
  • AstraZeneca
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Merck
  • Novartis
Other prominent vendors
  • Abbott
  • Amgen
  • AptarGroup
  • Biotest
  • Boehringer Ingelheim
  • Chiesi Farmaceutici
  • Cytos
  • Dainippon Sumitomo
  • Medicinova
  • Mylan
  • Novartis
  • Orchid Chemicals and Pharmaceuticals
  • Pfizer
  • Rottapharm Madaus
  • Skyepharma
  • Sosei
  • Sunovion
  • Teva Pharmaceutical
  • Theravance
  • Vectura
Key market driver
  • High prevalence of asthma
  • For a full, detailed list, view our report
Key market challenge
  • Unknown disease etiology
  • For a full, detailed list, view our report
Key market trend
  • Growing popularity of combination therapies
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Preventive Asthma Drugs Market 2015-2019

Technavio recognizes the following companies as the key players in the Global Preventive Asthma Drugs Market: AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, Merck and Novartis

Other Prominent Vendors in the market are: Abbott, Amgen, AptarGroup, Biotest, Boehringer Ingelheim, Chiesi Farmaceutici, Cytos, Dainippon Sumitomo, Medicinova, Mylan, Novartis, Orchid Chemicals and Pharmaceuticals, Pfizer, Rottapharm Madaus, Skyepharma, Sosei, Sunovion, Teva Pharmaceutical, Theravance, Vectura

Commenting on the report, an analyst from Technavio’s team said: “The popularity of combination therapies for the treatment of asthma will help in the market's growth. Drugs that fall under the category of ICS, LABA, and leukotriene receptor antagonists are frequently prescribed by physicians to control asthma.”

According to the report, the market is set to grow because of the high prevalence of asthma worldwide. The demand for drugs to treat and prevent asthma presents an opportunity to develop a therapy with better efficacy and safety profiles. The market expects to launch its robust pipeline of drug candidates for the management of asthma during the forecast period.

Further, the report states that growth may be hampered because of the disease's unknown origins. Finding a drug that targets the root cause of the disease has been difficult to find. Also, the patent expiry of some of the highest-selling drugs has resulted in the entry of generics, affecting market growth.

Companies Mentioned

AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, Merck, Novartis, Abbott, Amgen, AptarGroup, Biotest, Boehringer Ingelheim, Chiesi Farmaceutici, Cytos, Dainippon Sumitomo, Medicinova, Mylan, Novartis, Orchid Chemicals and Pharmaceuticals, Pfizer, Rottapharm Madaus, Skyepharma, Sosei, Sunovion, Teva Pharmaceutical, Theravance, Vectura

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
  • Product profiles
    • Accolate
    • Pulmicort
    • Symbicort
    • Xolair
    • Advair
    • Anoro Ellipta
    • Arnuity Ellipta
    • Breo Ellipta
    • Flovent
    • Serevent
    • Ventolin
    • Asmanex
    • Foradil
    • Dulera
    • Singulair
  • Disease overview
    • Understanding the disease
    • Symptoms
    • Pathophysiology
    • Epidemiology
    • Diagnosis
      • Table Major diagnostic procedures for asthma
    • Management
  • Pipeline Portfolio
    • Table Major drugs under development for asthma
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global preventive asthma drugs market ($ millions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by class of drug
    • Table Segmentation of global preventive asthma drugs market by class of drug
    • Table Segmentation of global preventive asthma drugs market by class of drug 2014
    • Table Global preventive asthma drugs market: Market share by class of drug 2014-2019 ($ millions)
  • ICS/LABA combination
    • Global ICS/LABA combination market
      • Table Global ICS/LABA combination market 2014-2019 ($ millions)
    • Immunosuppressants
    • Global immunosuppressants market
      • Table Global immunosuppressants market 2014-2019 ($ millions)
  • Leukotriene antagonists
    • Global leukotriene antagonists market
      • Table Global leukotriene antagonists market 2014-2019 ($ millions)
  • Mast cell stabilizers
    • Global mast cell stabilizers market
      • Table Global mast cell stabilizers market 2014-2019 ($ millions)
  • Inhaled corticosteroids
    • Global inhaled corticosteroids market
      • Table Global corticosteroids market 2014-2019 ($ millions)
  • Geographical segmentation
    • Global preventive asthma drugs market by geography 2014-2019
      • Table Global preventive asthma drugs market by geography 2014
      • Table Global preventive asthma drugs market: Market share by region 2014-2019 ($ millions)
    • Preventive asthma drugs market in Americas
      • Table Preventive asthma drugs market in Americas 2014-2019 ($ millions)
    • Preventive asthma drugs market in EMEA
      • Table Preventive asthma drugs market in EMEA 2014-2019 ($ millions)
    • Preventive asthma drugs market in APAC
  • Market drivers
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
  • Vendor landscape
    • Competitive scenario
      • Table Sales of Pulmicort in US 2011-2014 ($ millions)
      • Table Global sales of Pulmicort 2011-2014 ($ millions)
      • Table AstraZeneca: Key takeaways
      • Table Sales of Xolair in the US 2011-2014 ($ millions)
      • Table F. Hoffmann-La Roche: Key takeaways
      • Table Global sales of Ventolin 2011-2014 ($ millions)
      • Table Global sales of Flovent 2011-2014 ($ millions)
      • Table Global sales of Advair 2011-2014 ($ millions)
      • Table Global sales of Serevent 2011-2014 ($ millions)
      • Table GlaxoSmithKline: Key takeaways
      • Table Global sales of Asmanex 2011-2013 ($ millions)
      • Table Global sales of Dulera 2011-2013 ($ millions)
      • Table Global sales of Singulair 2011-2013 ($ millions)
      • Table Merck: Key takeaways
      • Table Sales of Xolair (ex-US) 2011-2014 ($ millions)
      • Table Key takeaways: Novartis
    • Other and future prominent vendors
  • Key vendor analysis
    • AstraZeneca
      • Table AstraZeneca: Business segmentation by revenue 2014
      • Table AstraZeneca: Business segmentation by revenue 2013 and 2014
      • Table AstraZeneca: Geographical segmentation by revenue 2014
    • F. Hoffmann-La Roche
    • GlaxoSmithKline
    • Merck
    • Novartis
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report